Radiopharmaceuticals for Skeletal Muscle PET Imaging

被引:2
|
作者
Park, Joo Yeon [1 ]
Park, Sun Mi [1 ]
Lee, Tae Sup [2 ]
Kang, Seo Young [1 ]
Kim, Ji-Young [1 ]
Yoon, Hai-Jeon [1 ]
Kim, Bom Sahn [1 ]
Moon, Byung Seok [1 ]
机构
[1] Ewha Womans Univ, Coll Med, Dept Nucl Med, Seoul 07804, South Korea
[2] Korea Inst Radiol & Med Sci, Div RI Applicat, Seoul 01812, South Korea
基金
新加坡国家研究基金会;
关键词
positron emission tomography; radiopharmaceutical; skeletal muscle atrophy; GLUCOSE-UPTAKE; BLOOD-FLOW; MANAGEMENT; MECHANISMS;
D O I
10.3390/ijms25094860
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The skeletal muscles account for approximately 40% of the body weight and are crucial in movement, nutrient absorption, and energy metabolism. Muscle loss and decline in function cause a decrease in the quality of life of patients and the elderly, leading to complications that require early diagnosis. Positron emission tomography/computed tomography (PET/CT) offers non-invasive, high-resolution visualization of tissues. It has emerged as a promising alternative to invasive diagnostic methods and is attracting attention as a tool for assessing muscle function and imaging muscle diseases. Effective imaging of muscle function and pathology relies on appropriate radiopharmaceuticals that target key aspects of muscle metabolism, such as glucose uptake, adenosine triphosphate (ATP) production, and the oxidation of fat and carbohydrates. In this review, we describe how [18F]fluoro-2-deoxy-D-glucose ([18F]FDG), [18F]fluorocholine ([18F]FCH), [11C]acetate, and [15O]water ([15O]H2O) are suitable radiopharmaceuticals for diagnostic imaging of skeletal muscles.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Special Issue: "Molecular Imaging in Oncology: Radiopharmaceuticals for PET and SPECT 2022"
    Zhang, Junbo
    PHARMACEUTICALS, 2024, 17 (01)
  • [42] Development of New PET radiopharmaceuticals for imaging monoamine oxidase-B
    Vasdev, Neil
    Sadovski, Oleg
    Parkes, Jun
    Moran, Matthew D.
    Meyer, Jeffrey H.
    Houle, Sylvain
    Wilson, Alan A.
    NEUROIMAGE, 2010, 52 : S16 - S16
  • [43] SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic
    Wang, Xiaobo
    Feng, Han
    Zhao, Shichao
    Xu, Junling
    Wu, Xinyu
    Cui, Jing
    Zhang, Ying
    Qin, Yuhua
    Liu, Zhiguo
    Gao, Tang
    Gao, Yongju
    Zeng, Wenbin
    ONCOTARGET, 2017, 8 (12) : 20476 - 20495
  • [44] Methods for the Incorporation of Carbon-11 To Generate Radiopharmaceuticals for PET Imaging
    Scott, Peter J. H.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2009, 48 (33) : 6001 - 6004
  • [45] Study of skeletal muscle behavior by PET/MRI
    Juan, David Garcia
    Trombella, Sara
    Delattre, Benedicte M. A.
    Seimbille, Yann
    Ratib, Osman
    2014 IEEE-EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS (BHI), 2014, : 61 - 64
  • [46] Skeletal Muscle Metastases detection by 18F-FDG PET-CT imaging
    Jaller, R.
    Domenech, A.
    Camacho, V.
    Flotats, A.
    Fernandez, A.
    Geraldo, L.
    Deportos, J.
    Carrio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S135 - S135
  • [47] ASSESSMENT OF SKELETAL-MUSCLE VIABILITY BY PET
    SMITH, GT
    WILSON, TS
    HUNTER, K
    BESOZZI, MC
    HUBNER, KF
    REATH, DB
    GOLDMAN, MH
    BUONOCORE, E
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (08) : 1408 - 1414
  • [48] Multiple and solitary skeletal muscle metastases on 18F-FDG PET/CT imaging
    Nocun, Anna
    Chrapko, Beata
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (11) : 1091 - 1099
  • [49] FLT PET/CT and FDG PET/CT of Skeletal Muscle Sarcoidosis
    Norikane, Takashi
    Nishiyama, Yoshihiro
    RADIOLOGY, 2021, 300 (03) : 512 - 512
  • [50] MR imaging of skeletal muscle metastases
    Williams, JB
    Youngberg, RA
    BuiMansfield, LT
    Pitcher, JD
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 168 (02) : 555 - 557